 Cindy Stowe
Concepts (204)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 16 | 2025 | 150 | 3.970 |
Why?
| | Students, Pharmacy | 12 | 2025 | 123 | 2.140 |
Why?
| | Curriculum | 13 | 2025 | 392 | 1.410 |
Why?
| | Educational Measurement | 6 | 2019 | 194 | 1.170 |
Why?
| | Competency-Based Education | 6 | 2025 | 28 | 0.980 |
Why?
| | Models, Educational | 2 | 2025 | 31 | 0.970 |
Why?
| | Pharmacists | 3 | 2025 | 141 | 0.850 |
Why?
| | Alprostadil | 2 | 2011 | 10 | 0.680 |
Why?
| | Constipation | 2 | 2011 | 37 | 0.670 |
Why?
| | Cystic Fibrosis | 3 | 2011 | 155 | 0.600 |
Why?
| | Cooperative Behavior | 1 | 2020 | 226 | 0.580 |
Why?
| | Program Evaluation | 3 | 2016 | 350 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.520 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.510 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2024 | 503 | 0.470 |
Why?
| | Thinking | 1 | 2014 | 19 | 0.440 |
Why?
| | Education, Medical, Undergraduate | 2 | 2008 | 85 | 0.440 |
Why?
| | Pharmacy | 3 | 2024 | 54 | 0.430 |
Why?
| | Personal Satisfaction | 2 | 2014 | 74 | 0.430 |
Why?
| | Pharmaceutical Services | 2 | 2023 | 50 | 0.400 |
Why?
| | Health Surveys | 1 | 2014 | 238 | 0.390 |
Why?
| | Humans | 40 | 2025 | 52114 | 0.360 |
Why?
| | Chlorides | 2 | 2008 | 43 | 0.330 |
Why?
| | Faculty | 3 | 2016 | 70 | 0.330 |
Why?
| | Anticonvulsants | 2 | 2000 | 133 | 0.300 |
Why?
| | Cesium | 1 | 2008 | 8 | 0.290 |
Why?
| | Quality of Life | 1 | 2014 | 878 | 0.280 |
Why?
| | Problem-Based Learning | 1 | 2008 | 48 | 0.280 |
Why?
| | Schools, Pharmacy | 5 | 2025 | 55 | 0.270 |
Why?
| | Electrocardiography | 1 | 2008 | 279 | 0.250 |
Why?
| | Students, Medical | 1 | 2008 | 156 | 0.240 |
Why?
| | Drugs, Generic | 1 | 2004 | 7 | 0.220 |
Why?
| | Omeprazole | 1 | 2004 | 16 | 0.220 |
Why?
| | Health Benefit Plans, Employee | 1 | 2004 | 15 | 0.220 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 21 | 0.220 |
Why?
| | Nonprescription Drugs | 1 | 2004 | 33 | 0.220 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2004 | 25 | 0.220 |
Why?
| | Blood Pressure | 2 | 2008 | 535 | 0.220 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 95 | 0.220 |
Why?
| | Proton Pump Inhibitors | 1 | 2004 | 86 | 0.210 |
Why?
| | Pilot Projects | 5 | 2017 | 712 | 0.190 |
Why?
| | Pharmacies | 1 | 2023 | 60 | 0.190 |
Why?
| | Amphetamines | 1 | 2002 | 26 | 0.190 |
Why?
| | Administrative Personnel | 1 | 2002 | 14 | 0.180 |
Why?
| | Methylphenidate | 1 | 2002 | 75 | 0.180 |
Why?
| | Phenytoin | 1 | 2000 | 16 | 0.170 |
Why?
| | Academic Medical Centers | 1 | 2002 | 147 | 0.170 |
Why?
| | Chloride Channels | 2 | 2011 | 26 | 0.170 |
Why?
| | Heart Rate | 1 | 2002 | 317 | 0.170 |
Why?
| | Young Adult | 5 | 2016 | 4307 | 0.170 |
Why?
| | Male | 18 | 2017 | 26652 | 0.170 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 179 | 0.170 |
Why?
| | Organizational Culture | 1 | 2020 | 44 | 0.160 |
Why?
| | Central Nervous System Stimulants | 1 | 2002 | 199 | 0.160 |
Why?
| | Empathy | 1 | 2020 | 47 | 0.160 |
Why?
| | Fructose | 1 | 2000 | 20 | 0.160 |
Why?
| | Confusion | 1 | 2000 | 19 | 0.160 |
Why?
| | Patient Care Team | 1 | 2002 | 271 | 0.160 |
Why?
| | Education, Distance | 1 | 2020 | 42 | 0.160 |
Why?
| | Acidosis | 1 | 2000 | 41 | 0.160 |
Why?
| | Leadership | 1 | 2020 | 104 | 0.150 |
Why?
| | Theophylline | 1 | 1999 | 18 | 0.150 |
Why?
| | Antitubercular Agents | 1 | 1999 | 84 | 0.150 |
Why?
| | Brain Injuries | 1 | 2000 | 158 | 0.150 |
Why?
| | Self Care | 1 | 2020 | 135 | 0.150 |
Why?
| | Female | 15 | 2017 | 28055 | 0.150 |
Why?
| | Tuberculosis | 1 | 1999 | 131 | 0.150 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 358 | 0.150 |
Why?
| | Vasodilator Agents | 1 | 1999 | 93 | 0.150 |
Why?
| | Clinical Competence | 3 | 2024 | 396 | 0.140 |
Why?
| | Communication | 1 | 2020 | 254 | 0.140 |
Why?
| | Down Syndrome | 1 | 1999 | 91 | 0.140 |
Why?
| | Teaching | 2 | 2019 | 113 | 0.140 |
Why?
| | Mobility Limitation | 1 | 2017 | 27 | 0.130 |
Why?
| | Infusion Pumps | 1 | 1996 | 12 | 0.130 |
Why?
| | Dobutamine | 1 | 1996 | 20 | 0.130 |
Why?
| | Focus Groups | 3 | 2025 | 195 | 0.130 |
Why?
| | Histamine H2 Antagonists | 3 | 2003 | 26 | 0.130 |
Why?
| | Adult | 7 | 2016 | 14095 | 0.120 |
Why?
| | Cardiotonic Agents | 1 | 1996 | 85 | 0.120 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2017 | 274 | 0.120 |
Why?
| | Dopamine | 1 | 1996 | 169 | 0.120 |
Why?
| | Pandemics | 1 | 2020 | 579 | 0.120 |
Why?
| | Hemodynamics | 1 | 1996 | 264 | 0.120 |
Why?
| | Psychometrics | 1 | 2016 | 229 | 0.110 |
Why?
| | Triazoles | 2 | 2005 | 113 | 0.100 |
Why?
| | Helping Behavior | 1 | 2013 | 8 | 0.100 |
Why?
| | Pyrimidines | 2 | 2005 | 198 | 0.100 |
Why?
| | Inflammation | 1 | 2017 | 641 | 0.100 |
Why?
| | Naloxone | 1 | 1993 | 78 | 0.100 |
Why?
| | Attitude | 1 | 2013 | 70 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1214 | 0.100 |
Why?
| | Antifungal Agents | 2 | 2005 | 346 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 1665 | 0.090 |
Why?
| | Famotidine | 2 | 2003 | 11 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2016 | 6610 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2011 | 5456 | 0.080 |
Why?
| | Liver Regeneration | 1 | 2010 | 47 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 39 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2010 | 84 | 0.080 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 38 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 187 | 0.080 |
Why?
| | Alzheimer Disease | 1 | 1993 | 331 | 0.080 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2010 | 117 | 0.070 |
Why?
| | Hepatocytes | 1 | 2010 | 190 | 0.070 |
Why?
| | Biphenyl Compounds | 1 | 2008 | 31 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 44 | 0.070 |
Why?
| | Tetrazoles | 1 | 2008 | 41 | 0.070 |
Why?
| | Self-Assessment | 1 | 2008 | 43 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2008 | 50 | 0.070 |
Why?
| | Peer Group | 1 | 2008 | 57 | 0.070 |
Why?
| | Program Development | 1 | 2008 | 164 | 0.070 |
Why?
| | Infant | 6 | 2007 | 3660 | 0.070 |
Why?
| | Child | 5 | 2008 | 7147 | 0.070 |
Why?
| | Acetaminophen | 1 | 2010 | 277 | 0.070 |
Why?
| | Antitussive Agents | 1 | 2007 | 8 | 0.070 |
Why?
| | Dextromethorphan | 1 | 2007 | 16 | 0.070 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2008 | 34 | 0.070 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 1 | 2006 | 5 | 0.060 |
Why?
| | Ceftazidime | 1 | 2006 | 7 | 0.060 |
Why?
| | Peritonitis | 1 | 2006 | 24 | 0.060 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2008 | 199 | 0.060 |
Why?
| | Delphi Technique | 1 | 2025 | 64 | 0.060 |
Why?
| | Adolescent | 5 | 2008 | 6681 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 104 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2008 | 332 | 0.060 |
Why?
| | Candidiasis | 1 | 2005 | 113 | 0.050 |
Why?
| | Health Occupations | 1 | 2024 | 19 | 0.050 |
Why?
| | Liver | 1 | 2010 | 1154 | 0.050 |
Why?
| | Professional Competence | 1 | 2024 | 42 | 0.050 |
Why?
| | Trichosporon | 1 | 2003 | 13 | 0.050 |
Why?
| | Learning | 1 | 2025 | 156 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1368 | 0.050 |
Why?
| | Hypertension | 1 | 2008 | 565 | 0.050 |
Why?
| | Mycoses | 1 | 2003 | 152 | 0.050 |
Why?
| | Metabolic Clearance Rate | 2 | 1999 | 67 | 0.050 |
Why?
| | Aging | 1 | 2007 | 701 | 0.050 |
Why?
| | United States | 2 | 2023 | 5168 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2005 | 218 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 714 | 0.040 |
Why?
| | Sleep | 1 | 2002 | 185 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2007 | 2859 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 212 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 796 | 0.040 |
Why?
| | Ranitidine | 1 | 1999 | 4 | 0.040 |
Why?
| | Copper Sulfate | 1 | 1999 | 3 | 0.040 |
Why?
| | Burns, Chemical | 1 | 1999 | 9 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 326 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 1999 | 44 | 0.040 |
Why?
| | North America | 1 | 1999 | 75 | 0.040 |
Why?
| | Feedback | 1 | 2019 | 52 | 0.040 |
Why?
| | Protein Binding | 1 | 2000 | 665 | 0.040 |
Why?
| | Stomach | 1 | 1999 | 82 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 386 | 0.040 |
Why?
| | Arkansas | 1 | 2004 | 2016 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2019 | 272 | 0.040 |
Why?
| | Child, Preschool | 3 | 2003 | 4001 | 0.040 |
Why?
| | Seizures | 1 | 2000 | 203 | 0.030 |
Why?
| | Losartan | 1 | 2017 | 27 | 0.030 |
Why?
| | Eicosapentaenoic Acid | 1 | 2017 | 24 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2017 | 131 | 0.030 |
Why?
| | College Admission Test | 1 | 2016 | 13 | 0.030 |
Why?
| | School Admission Criteria | 1 | 2016 | 35 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 718 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 925 | 0.030 |
Why?
| | Ego | 1 | 2013 | 4 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2013 | 107 | 0.020 |
Why?
| | Perception | 1 | 2013 | 120 | 0.020 |
Why?
| | Universities | 1 | 2013 | 172 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 227 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 600 | 0.020 |
Why?
| | Health Status | 1 | 2013 | 300 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 1996 | 611 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 118 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 163 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 169 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 492 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 2970 | 0.020 |
Why?
| | Dealkylation | 1 | 2007 | 2 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 975 | 0.020 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2007 | 21 | 0.020 |
Why?
| | Biotransformation | 1 | 2007 | 86 | 0.020 |
Why?
| | Cytokines | 1 | 2010 | 621 | 0.020 |
Why?
| | Animals | 2 | 2010 | 13332 | 0.020 |
Why?
| | Hemodialysis Solutions | 1 | 2006 | 2 | 0.020 |
Why?
| | Alleles | 1 | 2007 | 277 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2007 | 191 | 0.020 |
Why?
| | Genotype | 1 | 2007 | 563 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 1467 | 0.010 |
Why?
| | Aged | 1 | 2017 | 10142 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2003 | 192 | 0.010 |
Why?
| | Neutropenia | 1 | 2003 | 113 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2003 | 172 | 0.010 |
Why?
| | Infant, Premature | 1 | 2005 | 327 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 13028 | 0.010 |
Why?
| | Prospective Studies | 1 | 2006 | 2424 | 0.010 |
Why?
| | Poisoning | 1 | 1999 | 21 | 0.010 |
Why?
| | Mice | 1 | 2010 | 5877 | 0.010 |
Why?
| | Endoscopy, Digestive System | 1 | 1999 | 52 | 0.010 |
Why?
| | Gastroesophageal Reflux | 1 | 1999 | 48 | 0.010 |
Why?
| | Gastric Acidity Determination | 1 | 1998 | 12 | 0.010 |
Why?
| | Linear Models | 1 | 1999 | 290 | 0.010 |
Why?
| | Administration, Oral | 1 | 1999 | 453 | 0.010 |
Why?
|
|
Stowe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|